Tempest Therapeutics Inc

1
NAS:TPST (USA)  
$ 2.92 +0.0099 (+0.34%) 03:23 PM EST
At Loss
P/B:
3.16
Market Cap:
$ 65.32M
Enterprise V:
$ 52.70M
Volume:
291.41K
Avg Vol (2M):
332.48K
Trade In:
Volume:
291.41K
At Loss
Avg Vol (2M):
332.48K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for TPST ( Tempest Therapeutics Inc ) from 2021 to Jun 18 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Tempest Therapeutics stock (TPST) PE ratio as of Jun 18 2024 is 0. More Details

Tempest Therapeutics Inc (TPST) PE Ratio (TTM) Chart

To

Tempest Therapeutics Inc (TPST) PE Ratio (TTM) Historical Data

Total 749
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 9
Tempest Therapeutics PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-18 At Loss 2024-04-15 At Loss
2024-06-17 At Loss 2024-04-12 At Loss
2024-06-14 At Loss 2024-04-11 At Loss
2024-06-13 At Loss 2024-04-10 At Loss
2024-06-12 At Loss 2024-04-09 At Loss
2024-06-11 At Loss 2024-04-08 At Loss
2024-06-10 At Loss 2024-04-05 At Loss
2024-06-07 At Loss 2024-04-04 At Loss
2024-06-06 At Loss 2024-04-03 At Loss
2024-06-05 At Loss 2024-04-02 At Loss
2024-06-04 At Loss 2024-04-01 At Loss
2024-06-03 At Loss 2024-03-28 At Loss
2024-05-31 At Loss 2024-03-27 At Loss
2024-05-30 At Loss 2024-03-26 At Loss
2024-05-29 At Loss 2024-03-25 At Loss
2024-05-28 At Loss 2024-03-22 At Loss
2024-05-24 At Loss 2024-03-21 At Loss
2024-05-23 At Loss 2024-03-20 At Loss
2024-05-22 At Loss 2024-03-19 At Loss
2024-05-21 At Loss 2024-03-18 At Loss
2024-05-20 At Loss 2024-03-15 At Loss
2024-05-17 At Loss 2024-03-14 At Loss
2024-05-16 At Loss 2024-03-13 At Loss
2024-05-15 At Loss 2024-03-12 At Loss
2024-05-14 At Loss 2024-03-11 At Loss
2024-05-13 At Loss 2024-03-08 At Loss
2024-05-10 At Loss 2024-03-07 At Loss
2024-05-09 At Loss 2024-03-06 At Loss
2024-05-08 At Loss 2024-03-05 At Loss
2024-05-07 At Loss 2024-03-04 At Loss
2024-05-06 At Loss 2024-03-01 At Loss
2024-05-03 At Loss 2024-02-29 At Loss
2024-05-02 At Loss 2024-02-28 At Loss
2024-05-01 At Loss 2024-02-27 At Loss
2024-04-30 At Loss 2024-02-26 At Loss
2024-04-29 At Loss 2024-02-23 At Loss
2024-04-26 At Loss 2024-02-22 At Loss
2024-04-25 At Loss 2024-02-21 At Loss
2024-04-24 At Loss 2024-02-20 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss

Tempest Therapeutics Inc (TPST) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.